Shares of CymaBay Therapeutics Inc (NASDAQ:CBAY) have been given an average recommendation of “Buy” by the thirteen ratings firms that are covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 12 month target price among analysts that […]
